Corynebacterium bovis

The alkaloid K-252a (330) (see Scheme 2.85) was examined against several microbes and found to be active against Micrococcus luteus, Micrococcus flavus FDA16, and Corynebacterium bovis 1810 with a MIC of 6.25gg/mL (314). 

BCG is a viable strain of Mycobacterium bovis that has been used for immunization against tuberculosis. It has also been employed as a nonspecific adjuvant or immunostimulant in cancer therapy but has been successful only in intravesical therapy for superficial bladder cancer. BCG appears to act at least in part via activation of macrophages to make them more effective killer cells in concert with lymphoid cells in the cellular efferent limb of the immune response. Lipid extracts of BCG as well as nonviable preparations of Corynebacterium parvum may have similar nonspecific immunostimulant properties. A chemically defined derivative of the BCG cell wall, [Lys18]-muramyl dipeptide, has been licensed in Japan to enhance bone marrow recovery after cancer chemotherapy. 

Senaldi G, Shaklee CL, Mak TW, Ulich TR. Corynebacterium parvum- and Mycobacterium bovis Bacillus Calmette and Guerin-induced granuloma formation in mice lacking CD4 and CDS. Cell Immunol 1999 193 155-161. 

Tateno T, Fukuda H, Kondo A. (2007b). Direct production of L-lysine from raw com starch by Corynebacterium glutamicum secreting Streptococcus bovis a-amylase using cspB promoter and signal sequence. Appl Microbiol Biotechnol, 77, 533-541. 

---